More importantly, our data showed that the interference of MCB1 increased FGFR1 and VEGFR3 activation and sensitized hepatoma cells to targeted drugs, suggesting that the interaction between MCB1 and FGFR1 or VEGFR3 determines the HCC cell response to sorafenib and lenvatinib. Here, FLT4 is linked to hepatocellular carcinoma.